Table 1.
Systemic sclerosis patient overview.
| # | ID | SSc variant1 | ENA2 | CXCR3 Ab (U/ml) |
|---|---|---|---|---|
| 1 | 51_SSC | limited | anti-Scl70 | 15.213 |
| 2 | 80_SSC | limited | anti-Scl70 | 3.775 |
| 3 | 88_SSC | diffuse with myositis overlap | anti-Ro52 | 5.156 |
| 4 | 96_SSC | diffuse | anti-Scl70 | 4.008 |
| 5 | 110_SSC | limited | anti-CENP-B | 5.023 |
| 6 | 117_SSC | limited | anti-CENP-B | 6.950 |
| 7 | 202_SSC | limited | anti-Scl70 | 15.399 |
| 8 | 215_SSC | diffuse | anti-Scl70 | 3.853 |
| 9 | 216_SSC | limited | anti-CENP-B | 3.805 |
| 10 | 226_SSC | limited | anti-CENP-B | 5.295 |
| 11 | 235_SSC | limited | anti-CENP-B | 6.982 |
| 12 | 279_SSC | limited | anti-RNP/sm+ | 7.984 |
| anti-Sm+ | ||||
| anti-PmScl75 | ||||
| 13 | 313_SSC | diffuse | anti-Scl70 | 6.080 |
| 14 | 327_SSC | limited | anti-CENP-B | 7.770 |
| 15 | 332_SSC | limited | anti-Scl70 | 4.350 |
| 16 | 335_SSC | diffuse | anti-Scl70 | 4.828 |
| 17 | 368_SSC | limited | anti-Scl70 | 4.299 |
| 18 | 373_SSC | limited | anti-CENP-B | 4.084 |
| 19 | 383_SSC | diffuse | dense fine speckled pattern | 8.065 |
| 20 | 384_SSC | limited | anti-Scl70 | 5.381 |
| 21 | SKL011 | limited | anti-CENP-B | 6.577 |
| 22 | SKL024 | limited | anti-CENP-B | 2.948 |
| 23 | SKL028 | diffuse | anti-Scl70 | 2.876 |
| 24 | SKL033 | diffuse | n.d. | 12.163 |
| 25 | SKL034 | diffuse | anti-Scl70 | 6.542 |
| 26 | SKL102 | limited | anti-CENP-B | 25.575 |
| 27 | SKL103 | UCTD | n.d. | 18.678 |
| 28 | SKL109 | limited | anti-CENP-B | 4.042 |
| 29 | SKL111 | MCTD | n.d. | 13.025 |
| 30 | SKL117 | limited | anti-CENP-B | 38.758 |
| 31 | SKL157 | limited | anti-CENP-B | 11.802 |
| 32 | SKL224 | limited | anti-CENP-B | 3.717 |
Limited or diffuse systemic sclerosis, undifferentiated connective tissue disease (UCTD), mixed connective tissue disease (MCTD).
Reactivity against specific extractable nuclear antigens (ENA). n.d., not differentiated. All SSc patients were ANA-positive.